These findings suggest that monitoring soluble TFF1 levels in the aqueous humor of RB patients under therapy could serve as a potential biomarker to assess treatment efficacy and predict therapeutic outcomes in non-enucleated RB tumors. The gene discussed is TFF1; the disease is retinoblastoma.